SUMMARY OF CHANGES
A5401 FINAL Version 4.0, Dated 2/22/21
Adaptive Platform Treatment Trial for Outpatients with COVID-19, (Adapt Out COVID)

The main purpose of this amendment is to:

- add a new study agent to the protocol
- incorporate previous Letters of Amendment

The following changes have been made to A5401. These changes, except for deletions, are noted in bold in the protocol document. Minor corrections were made in the protocol document for clarification and editorial purposes; these revisions are not reflected in this list.

1. The COVER PAGE, SIGNATURE PAGE, PROTOCOL TEAM ROSTER, and REFERENCES (master protocol) sections have been updated

2. Address for protocol email group has been removed from the protocol: STUDY MANAGEMENT section

3. “No history of COVID-19 vaccination” was added to the definition of “higher risk”: SCHEMA-POPULATION (master protocol)

4. The definition of “higher risk” with respect to smoking was updated: SCHEMA- POPULATION (master protocol)

5. Acceptable tests for presence of SARS-CoV-2 virus have been clarified: SCHEMA-POPULATION (master protocol), Section 4.1.1.3 (master protocol), Section 4.1.2.2 (master protocol)

6. Symptom duration for entry has been reduced to 8 days (192 hours): SCHEMA-POPULATION (master protocol), Section 4.1.1.4 (master protocol), Section 6.2.2 (master protocol)

7. Background information has been updated to note recent approval of COVID-19 treatments: Section 2.1 (master protocol)

8. For infused agents, the study now includes a transition into a larger phase III evaluation, without a pause in enrollment, if safety data are acceptable as determined by the study’s DSMB: SCHEMA-OUTCOME MEASURES (master protocol), Section 3.1 (master protocol), Figure 3.0-1 (master protocol), Section 3.2 (master protocol), Section 10.5.1 (master protocol), Section 10.5.2 (master protocol), Figure 10.5.2-1 (master protocol)

9. Restriction on vaccination prior to Entry was removed: Section 4.1.2.6 (master protocol) removed and subsequent sections renumbered.

10. Instructions for protocol registration were updated: Section 4.2 (master protocol)

11. Collection of zinc and Vitamin D levels were removed: Table 6.1-1 (master protocol, APPENDIX IV, APPENDIX VI, APPENDIX VIII, APPENDIX X, APPENDIX XII), Table 6.1-2 (master protocol, APPENDIX IV, APPENDIX VI), Section 1.3.11 (master protocol, removed), Section 6.3.14 (master protocol), APPENDIX I (WHAT DO I HAVE TO DO IF I AM IN THIS STUDY?)

12. A post-acute COVID assessment was added: Table 6.1-1 (master protocol, APPENDIX IV, APPENDIX VI, APPENIDX VIII, APPENDIX X, APPENDIX XII), Table 6.1-2 (master protocol, APPENDIX IV, APPENDIX VI), Section 6.3.2, APPENDIX I (WHAT DO I HAVE TO DO IF I AM IN THIS STUDY?), APPENDIX V (ARE THERE ANY ADDITIONAL STUDY

PROCEDURES IF I RECEIVE BRII-196 and BRII-198 OR PLACEBO?), APPENDIX VII (ARE THERE ANY ADDITIONAL STUDY PROCEDURES IF I RECEIVE AZD7442 OR PLACEBO?), APPENDIX IX (ARE THERE ANY ADDITIONAL STUDY PROCEDURES IF I RECEIVE AZD7442 OR PLACEBO?), APPENDIX XI (ARE THERE ANY ADDITIONAL STUDY PROCEDURES IF I RECEIVE SNG001 OR PLACEBO?), APPENDIX XIII ARE THERE ANY ADDITIONAL STUDY PROCEDURES IF I RECEIVE CAMOSTAT OR PLACEBO?)

13. Instructions for Medical History were updated: Section 6.3.3 (master protocol)

14. New guidance was added to allow sites to determine the location of study visits (in person or remote): Section 6.2.3 (master protocol), Section 6.3 (master protocol), APPENDIX I (WHAT DO I HAVE TO DO IF I AM IN THIS STUDY?)

15. Instructions for targeted physical exam were updated: Section 6.3.6 (master protocol), APPENDIX I (WHAT DO I HAVE TO DO IF I AM IN THIS STUDY?)

16. Instructions for Collection of Study Diary were updated: Section 6.3.11 (master protocol)

17. The Phase II primary outcome measures were updated to correct the symptom outcome definition: Section 10.2.1.1 (master protocol), Section 10.4.1 (master protocol)

18. The Phase II and III secondary outcome measures were updated to remove duration of fever: Section 10.2.3.4 (master protocol) was removed (and subsequent secondary outcome measures renumbered)

19. Guidance on receipt of future vaccination was updated: APPENDIX I (WHAT ARE THE RISKS OF THE STUDY?), APPENDIX III (WHAT ARE THE RISKS OF BAMLANIVIMAB?), APPENDIX V (WHAT ARE THE RISKS OF BRII-196 and BRII-198?), APPENDIX VII (WHAT ARE THE RISKS OF AZD7442?), APPENDIX IX (WHAT ARE THE RISKS OF AZD7442?)

20. LY3819253 was changed to bamlanivimab throughout the protocol: SIGNATURE PAGE, APPENDIX II, APPENDIX III, APPENDIX IV, APPENDIX XVI

21. Designation of site visits as “R/P” (remote or in-person) was removed from the Schedules of Evaluations: Table 6.1-1 (APPENDIX II, APPENDIX IV, APPENDIX VI, APPENDIX VIII, APPENDIX X, APPENDIX XII), Table 6.1-2 (APPENDIX II, APPENDIX IV, APPENDIX VI)

22. References to BRII-196 and BRII-198 50mg/mL that were removed with LOA #1 to Version 2.0 were restored: APPENDIX IV (Section 5.2.1, Section 5.2.2.3, Section 5.2.2.6 (and section 5.2 renumbered accordingly))

23. Windows were added around collection of vital signs: APPENDIX IV (Section 6.3.9), APPENDIX VI (Section 6.3.9), APPENDIX VIII (Section 6.3.9)

24. Windows were added around collection of PK samples: APPENDIX IV (Section 6.3.16), APPENDIX VI (Section 6.3.15), APPENDIX VIII (Section 6.3.15)

25. Instructions were added for recording adverse events: APPENDIX IV (new section 7.3), APPENDIX VI (new section 7.3), APPENDIX VIII (new section 7.3), APPENDIX X (new section 7.3), APPENDIX XII (new section 7.3)

26. Instructions were added for monitoring of vital signs during infusion: Appendix VI (Section 6.3.9).

27. Week 36, 48, and 72 visits were added for assessment of safety and post-acute COVID:

APPENDIX V (ARE THERE ANY ADDITIONAL STUDY PROCEDURES IF I RECEIVE BRII-196 and BRII-198 OR PLACEBO?), APPENDIX VII (ARE THERE ANY ADDITIONAL STUDY PROCEDURES IF I RECEIVE AZD7442 OR PLACEBO?), APPENDIX IX (ARE THERE ANY ADDITIONAL STUDY PROCEDURES IF I RECEIVE AZD7442 OR PLACEBO?), APPENDIX X (Table 6.1-1), APPENDIX XI (ARE THERE ANY ADDITIONAL STUDY PROCEDURES IF I RECEIVE SNG001 OR PLACEBO FOR SNG001?), APPENDIX XII (Table 6.1-1), APPENDIX XIII ARE THERE ANY ADDITIONAL STUDY PROCEDURES IF I RECEIVE CAMOSTAT OR PLACEBO?)

28. Duration of study visit was updated to 72 weeks: APPENDIX X (SCHEMA-DURATION), APPENDIX XI (HOW LONG WILL I BE IN THIS STUDY?), APPENDIX XII (SCHEMA-DURATION), APPENDIX XIII (HOW LONG WILL I BE IN THIS STUDY?)

29. A correction was made to note that PK analyses will be done on stored samples: APPENDIX X (Section 6.3.15), APPENDIX XI (ARE THERE ANY ADDITIONAL STUDY PROCEDURES IF I RECEIVE SNG001 OR PLACEBO FOR SNG001?)

30. Protocol was updated to allow for the first dose of SNG study agent to be taken at the clinic: APPENDIX X (Section 5.1.2, Administration), APPENDIX XI (ARE THERE ANY ADDITIONAL STUDY PROCEDURES IF I RECEIVE SNG001 OR PLACEBO FOR SNG001?)

31. The description of study visits on Days 7, 14, and 28 were updated: APPENDIX XI (ARE THERE ANY ADDITIONAL STUDY PROCEDURES IF I RECEIVE SNG001 OR PLACEBO FOR SNG001?)

32. SAB-185 has been added as a study agent: Cover Page, SIGNATURE PAGE, PROTOCOL TEAM ROSTER, APPENDIX XIV, APPENDIX XV, APPENDIX XVI

SUMMARY OF CHANGES
A5401 FINAL Version 5.0, Dated 4/2/21
Adaptive Platform Treatment Trial for Outpatients with COVID-19, (Adapt Out COVID)

The main purpose of this amendment is to:

- add a new study agent to the protocol
- incorporate edits to the SAB appendix that were requested by the FDA
- Update appendices with information contained in recent IB updates

The following changes have been made to A5401. These changes, except for deletions, are noted in bold in the protocol document. Minor corrections were made in the protocol document for clarification and editorial purposes; these revisions are not reflected in this list.

1. AZ appendices were updated to reflect recent updates to the IB: APPENDIX VI, APPENDIX VIII
2. AZ appendices were updated to clarify instructions for collection of vital signs during infusion: APPENDIX VI
3. AZ IM appendix was updated to clarify administration instructions: APPENDIX VIII
4. Camostat appendix was updated to clarify instructions for assessment of adherence: APPENDIX XII
5. Additional PK data was added to SAB Rationale: APPENDIX XIV
6. PK study was added to Day 1 of SAB Schedule of Evaluations: APPENDIX XIV, APPENDIX XV
7. SAB appendix was updated to clarify instructions for management of hypersensitivity: APPENDIX XIV
8. BMS-986414 and BMS-986413 have been added as study agents: Cover Page, SIGNATURE PAGE, TABLE OF CONTENTS, PROTOCOL TEAM ROSTER, APPENDIX XVI, APPENDIX XVII, APPENDIX XVIII

SUMMARY OF CHANGES
A5401 FINAL Version 6.0, Dated 4/30/21
Adaptive Platform Treatment Trial for Outpatients with COVID-19, (Adapt Out COVID)

The main purpose of this amendment is to:

- remove self-collected anterior nasal swabs from phase II evaluations
- remove dedicated sample collection for plasma SARS-CoV-2 RNA from phase II and phase III
- revise eligibility criteria for all agents currently in phase II evaluation to restrict enrollment to non-high risk participants only, as is already the case for BMS-986414+BMS-986413
- indicate that enrollment to all agents other than BRII-196 + BRII-198 will stop after phase II enrollment is complete and interim analyses during phase II for graduation or pause/no pause determination will not be conducted

The following changes have been made to A5401. These changes, except for deletions, are noted in bold in the protocol document. Minor corrections were made in the protocol document for clarification and editorial purposes; these revisions are not reflected in this list.

1. Symptom duration for eligibility has been decreased to 7 days of symptoms: SCHEMA (POPULATION), Section 4.1.1.4, Section 6.2.2

2. Self-collected anterior nasal swabs were removed from phase II evaluations: Section 1.2.3, Section 1.3, Table 6.1-1, Section 6.3.10, Section 6.3.13, Section 10.2.3, APPENDIX I (SCHEMA), APPENDIX I (WHAT DO I HAVE TO DO IF I AM IN THIS STUDY?), APPENDIX I (IF YOU ARE IN THE FIRST PART OF THE STUDY), APPENDIX I (WILL I RECEIVE THE RESULTS OF ANY TESTS?), APPENDIX IV (TABLE 6.1-1), APPENDIX VI (Table 6.1-1), APPENDIX VIII (Table 6.1-1). APPENDIX X (Section 6.1-1), APPENDIX XII (Section 6.1-1), APPENDIX XIV (Table 6.1-1), APPENDIX XVI (Table 6.1-1)

3. Objectives were added to examine post-acute COVID symptoms: Section 1.3, Section 10.2.4

4. Dedicated sample collection for plasma SARS-CoV-2 RNA was removed from phase II and phase III: Section 1.3, Table 6.1-1, Table 6.1-2, Section 6.3.13, Section 6.3.16, Section 10.2.3.7, Section 10.2.4, APPENDIX I (WHAT DO I HAVE TO DO IF I AM IN THIS STUDY?), APPENDIX I (IF YOU ARE IN THE FIRST PART OF THE STUDY), APPENDIX I (WILL I RECEIVE THE RESULTS OF ANY TESTS?), APPENDIX IV (Table 6.1-1 and Table 6.1-2), APPENDIX VI (Table 6.1-1 and Table 6.1-2), APPENDIX VIII (Table 6.1-1), APPENDIX X (Table 6.1-1), APPENDIX XII (Table 6.1-1), APPENDIX XIV (Table 6.1-1 and Table 6.1-2), APPENDIX XVI (Table 6.1-1)

5. Eligibility criteria for all agents currently in phase II evaluation was revised to restrict enrollment to non-high risk participants only: SCHEMA (POPULATION), Section 1.3.5, Section 3.3, Section 10.3, APPENDIX VI (Section 4.1.1 and Section 4.1.2), APPENDIX VIII (Section 4.1.2), APPENDIX X (Section 4.1.2), APPENDIX XII (Section 4.1.2), APPENDIX XIV (Section 4.1.2), APPENDIX XVI (Section 4.1.2)

6. Enrollment to all agents other than BRII-196 + BRII-198 will stop after phase II enrollment is complete and interim analyses during phase II for graduation or pause/no pause determination will not be conducted: SCHEMA (DESIGN, STRATIFICATION, SAMPLE SIZE, OUTCOME MEASURES), Section 1.1.4, Section 1.2.5, Section 1.2.7, Section 1.3.3, Section 2.2, Section 3.1, Section 3.2, Section 10.1, Section 10.4.2, Section 10.5, Section 10.6, Section 10.6.3,

7. Language was added to explain what will happen to stored samples upon withdrawal of consent for genetic testing or use of stored samples: APPENDIX I (IF YOU ARE IN THE FIRST PART OF THE STUDY), APPENDIX I (IF YOU ARE IN THE SECOND PART OF

THE STUDY), APPENDIX I (ATTACHMENT A)

8. Instructions on collection of post-infusion Day 0 PK samples and Day 1 PK samples, as applicable per investigational agent, were added: APPENDIX IV (Section 6.3.16), APPENDIX VI (Section 6.3.15), APPENDIX VIII (Section 6.3.15), APPENDIX XIV (Section 6.3.15), APPENDIX XVI (Section 6.3.15)

9. The protocol was updated to report a recent SUSAR of bronchospasm with SNG001: APPENDIX X (Section 2.2), APPENDIX XI (WHAT ARE THE RISKS OF SNG001?)

10. The protocol was updated to add bronchospasm as an AESI for SNG001: APPENDIX X (Section 7.1)

11. Information on variance in concentration by lot and updated preparation instructions were added to the SAB-185 appendix: APPENDIX XIV (Section 5.2.1, Section 5.2.2.1, Section 5.2.2.3, Section

12. Post-administration monitoring for BMS-986414+BMS-986413 was increased from 1 to 2 hours, as requested by the FDA: APPENDIX XVI (Section 6.3.9), APPENDIX XVII (ARE THERE ANY ADDITIONAL STUDY PROCEDURES IF I RECEIVE BMS-986414 and BMS-986413 OR PLACEBO?)

13. The visit window for Day 28 was corrected on the SOE for BMS-986414+BMS-986413: APPENDIX XVI (Table 6.1-1)

SUMMARY OF CHANGES
A5401 FINAL Version 7.0, Dated 6/29/21
Adaptive Platform Treatment Trial for Outpatients with COVID-19, (Adapt Out COVID)

The main purpose of this amendment is to:

- Update the study design

The following changes have been made to A5401. These changes, except for deletions, are noted in bold in the protocol document. Minor corrections were made in the protocol document for clarification and editorial purposes; these revisions are not reflected in this list.

1. The SIGNATURE PAGE, TABLE OF CONTENTS, PROTOCOL TEAM ROSTER, and REFERENCES (master protocol, Appendix XIII, Appendix XV, Appendix XVII), SIGNATURE PAGE – STUDY DRUGS (Appendix XIX) sections have been updated.

2. Phase II design has been updated to lower risk participants, placebo control, superiority design, graduation based on virology and clinical outcomes, sample size 110 participants: SCHEMA (DESIGN), SCHEMA (SAMPLE SIZE), SCHEMA (OUTCOME MEASURES), Section 3.1, Section 3.3, Section 5.0, Section 10.1, Section 10.2, Section 10.3, Section 10.4, Section 10.5, Section 10.6, Appendix I, Appendix XII, Appendix XV, Appendix XVII, Appendix XVIII

3. Phase III study design has been updated to higher risk participants, unblinded active comparator, non-inferiority comparison, sample size 600-800 participants: SCHEMA (DESIGN), SCHEMA (SAMPLE SIZE), SCHEMA (OUTCOME MEASURES), Section 2.1, Section 3.1, Section 3.3, Section 5.0, Section 10.1, Section 10.2, Section 10.3, Section 10.4, Section 10.5, Section 10.6, new Appendix II, Appendix XII, Appendix XIII, Appendix XV, Appendix XVII, Appendix XVIII

4. Study duration has been extended to 72 weeks for all agents except bamlanivimab to allow for assessment of post-acute COVID: SCHEMA (DURATION), Section 6.1, Section 6.2.3, Section 6.3.12, Appendix I, new Appendix II,

5. Stratification by country has been added: SCHEMA (STRATIFICATION)

6. Definition of “higher risk” of progression to hospitalization or death has been updated: SCHEMA (POPULATION), Section 6.3.3, Appendix V,

7. Phase II and III secondary objectives and outcome measures have been updated: Section 1.2, Section 2.2, Section 10.2.3

8. Phase II and III exploratory objectives have been updated: Section 1.3

9. New background information has been added regarding the COVID-19 pandemic and current EUA agents; Section 2.1, Appendix I

10. Process and criteria for graduation from Phase II to Phase III have been updated: Section 3.2

11. Exclusion criteria have been updated to noted exclude prohibited meds and systemic or inhaled steroids: Section 4.1.2.4

12. Exclusion criteria have been updated to note that COVID-19 vaccines are not exclusionary: Section 4.1.2.6

13. Pharmacy considerations for active comparator have been added: Section 5.1, Section 5.2, Section 5.3, Appendix XI, Appendix XV, Appendix XVII

14. Prohibited medications have been updated: Section 5.4

15. Allowance was added that specific agents may be removed provided that they are not clinically relevant to the primary evaluation of safety and efficacy of the agents under investigation: Section 6.0

16. The following were removed from the Phase II and Phase III SOEs (Table 6.1-1, Table 6.1-2):
    - Household Infection and Linkage Report (Week 12, Week 24, Premature Study D/C (After Day 28 Visit))
    - Staff Collected NP Swab (Day 28)
    - Inflammation Markers
    - Coagulation Markers

    Evaluations were also removed from Appendix I and new Appendix II

17. The following were added to the Phase II and Phase III SOEs (Table 6.1-1, Table 6.1-2):
    - The visit window for Day 28 was updated
    - Assessments formally noted as “Clinical Assessments” have been enumerated
    - Post-acute COVID assessments have been added to additional time points
    - Stored PBMCs (Selected Sites) have been added to “Premature Study D/C (After Day 28 Visit) (Table 6.1-1)
    - Self-Collected Nasal Swab (Day 0, Day 3) changed to Staff-Collected NP Swab (Table 6.1-2)
    - Stored Plasma and Serum at Day 3 (Table 6.1-2)
    - Hematology, chemistry, pregnancy testing (Table 6.1-2)

    Evaluations were also added to Appendix I and new Appendix II

18. Instructions for assessments formally noted as “Clinical Assessments” have been updated: Section 6.3.6

19. Participants will no longer self-collect nasal swabs: Section 6.3.10, Section 6.3.14, Section 10.2.1.2, Appendix I, new Appendix II,

20. Instructions have been added for Hematology, Chemistry, and Pregnancy Testing (Section 6.3.15)

21. Post-Acute COVID Assessment was moved to its own section and subsequent items in Section 6.3 were renumbered (including in appendices).

22. Adverse Events of Special Interest for the active comparator have been added: Section 7.1

23. Instructions for recording adverse events have been updated: Section 7.3 (and instructions for recording adverse events have been removed from the agent-specific appendices; all agents will follow the instructions in the master protocol).

24. Instructions for follow up of participants reporting AEs have been updated: Section 7.4

25. Guidance for clinical management has been updated to include casirivimab plus imdevimab: Section 8.0, Section 8.1, Section 8.2, Section 8.3, Section 8.4

26. The sample informed consents for Phase II and Phase III have been separated into two documents: New Appendix II and subsequent appendices renumbered

27. Options available to participants instead of study participation have been updated: Appendix I, new Appendix II

28. Participant information on treatment assignment has been updated: Appendix I, new Appendix II

29. Participant information on withdrawal of consent has been updated: Appendix I, new Appendix II

30. Participant information on availability of compensation in the event of injury was updated: Appendix I, new Appendix II

31. Notation was added that no more participants will enroll in bamlanivimab: Appendix IV

32. Notation was added that no more participants will enroll in Brii: Appendix VI

33. Notation was added that no more participants will enroll in AZ IV: Appendix VIII

34. Notation was added that no more participants will enroll in AZ IM: Appendix X

35. Notation was added that no more participants will enroll in camostat: Appendix XIV

36. Brii will continue to enroll using its current design, stratification, and SOE: Appendix V (SCHEMA, Section 6.1, Section 6.3, Section 10.4, Section 10.5)

37. There is no Phase III evaluation for AZ IV or AZ IM: Appendix VII, Appendix IX

38. Exploratory objectives for Synairgen have been updated: Appendix XI

39. Inclusion/exclusion for Synairgen have been updated: Appendix XI

40. Outcome measures for Synairgen have been updated: Appendix XI

41. Exclusion for camostat have been updated: Appendix XIII

42. Secondary outcome analyses for camostat have been updated: Appendix XIII

43. Considerations for graduation of SAB have been updated: Appendix XV

44. References to BMS-986414 and BMS-986413 were updated to BMS-986414 (C135-LS) and BMS-986413 (C144-LS)

45. Rationale for BMS agents has been updated: Appendix XVII

46. Considerations for graduation of BMS have been updated: Appendix XVII

47. Inclusion/exclusion for BMS have been updated: Appendix XVII

48. Instructions for BMS agent administration, formulation, storage, and preparation have been updated: Appendix XVII

49. BMS pharmacology plan has been updated: Appendix XVII

50. Risks of BMS have been updated (statement removed that BMS has not been given to persons who have tested positive for COVID-19 and are at risk for developing severe COVID-19): Appendix XVIII

SUMMARY OF CHANGES
A5401 FINAL Version 8.0, Dated 25Feb2022
Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID)

The main purpose of this amendment is to:

- Update the study design
- Incorporate previous Letters of Amendment and Clarification Memos

The following changes have been made to A5401. These changes, except for deletions, are noted in bold in the protocol document. Minor corrections were made in the protocol document for clarification and editorial purposes; these revisions are not reflected in this list.

1. The TABLE OF CONTENTS, PROTOCOL TEAM ROSTER, and REFERENCES (master protocol, Appendix XV) sections have been updated.

2. The study design has been updated to a superiority design comparing agents in phase III to placebo, allowing for standard of care after study entry: SCHEMA (DESIGN), SCHEMA (SAMPLE SIZE), Section 1.3, Section 2.1, Section 2.2, Section 3.1, Figure 3.1-1, Section 3.3, Section 5.0, Section 5.1, Section 5.2, Section 5.3, Section 10.1, Section 10.3, Section 10.4.2, Section 10.5.2, Section 10.6, Section 10.6.2, APPENDIX II, Section 5.1 (Appendix XI), Section 5.2 (Appendix XI), Section 5.3 (Appendix XI), Section 3.4 (Appendix XV), Section 5.1 (Appendix XV), Section 5.2 (Appendix XV), Section 5.3 (Appendix XV), Section 6.1 (Appendix XV), Appendix XVI

3. The definition of “higher risk” has been refined: SCHEMA (POPULATION)

4. Secondary objectives have been updated: Section 1.2, Section 1.2 (Appendix XI)

5. Exploratory objectives have been updated: Section 1.3 (Appendix XI)

6. Study background has been updated to include updated epidemiology and information on the Omicron variant: Section 2.1

7. Requirements for documentation of SARS-CoV-2 infection have been updated: Section 4.1.1.3

8. Requirements for seeking available COVID-19 treatment have been added: Section 4.1.1.6, Appendix II

9. Requirements for prohibited medications have been updated: Section 4.1.2.4, Section 5.4.1, Section 9.2

10. Requirements for oxygen saturation at entry have been updated: Section 4.1.2.5, Section 6.3.6

11. Requirements for prior receipt of COVID-19 treatment have been added: Section 4.1.2.6

12. Requirements for recording concomitant medications have been updated: Section 5.4, Section 6.3.6

13. Instructions have been added for participants who received casirivimab plus imdevimab under protocol Version 7: Table 6.1-2

14. Complete physical exam has been replaced with physical exam: Section 6.1, Section 6.3.6, Section 6.1 (Appendix V)

15. Requirements for following and recording pregnancy and outcomes have been updated: Section 6.3.15, Section 8.3, Section 8.3 (Appendix XI), Section 8.3 (Appendix XV), Section 8.3 (Appendix XVII), Appendix XVI (ARE THERE RISKS RELATED TO PREGNANCY OR BREASTFEEDING), Appendix XVII ((ARE THERE RISKS RELATED TO PREGNANCY OR BREASTFEEDING)

16. Instructions for reporting AEs have been updated: Section 7.1, Section 7.2, Section 7.3

17. Instructions for clinical management of side effects have been updated: Section 8.2

18. Instructions for breastfeeding have been updated: Section 8.4

19. Phase II primary outcome measures have been updated: Section 10.2.1.1

20. Secondary outcome measures have been updated: Section 10.2.3.7, Section 10.2.3.13, Section 10.6.3 (Appendix XI)

21. Guidance for unblinding has been updated: Section 10.7

22. Information on confidentiality of participant data has been updated: Appendix I (WHAT ABOUT CONFIDENTIALITY), Appendix II (WHAT ABOUT CONFIDENTIALITY)

23. Guidance on future vaccination has been updated: Appendix II (WHAT ARE THE RISKS OF THE STUDY), APPENDIX XVI (WHAT ARE THE RISKS OF SAB-185)

24. Information on other available treatments has been updated: Appendix II (WHAT OTHER CHOICES DO I HAVE BESIDES THIS STUDY)

25. Guidance was added that phase III evaluation of SNG001 will be initiated under a future protocol version: Appendix XI

26. Background information for study agents has been updated: Section 2.2 (Appendix XI)

27. Instructions for administration of SNG001 have been updated: Section 6.3.9 (Appendix XI), Appendix XII (IF YOU ARE IN THE FIRST PART OF THE STUDY), Appendix XII (IF YOU ARE IN THE SECOND PART OF THE STUDY)

28. Instructions for the return of SNG001 administration materials has been added: Appendix XII (IF YOU ARE IN THE SECOND PART OF THE STUDY)

29. Risk information for SNG001 has been updated: Appendix XII (WHAT ARE THE RISKS OF SNG001)

30. Study design considerations for SAB-185 have been updated: Section 3.4 (Appendix XV)

31. Instructions for regimen and duration of investigational agent have been added: Section 5.1.1.1 (Appendix XV), Section 5.1.1.2 (Appendix XV)

32. Instructions for administration and preparation of investigational agent to ensure blinding have been clarified: Section 5.1.2 (Appendix XV), Section 5.2.2.1 (Appendix XV), Section 5.2.2.2 (Appendix XV), Section 5.2.2.3 (Appendix XV), Section 5.2.2.4 (Appendix XV)

33. Instructions for Schedule of Evaluations have been updated: Section 6.1 (Appendix XV), Table 6.1-2 (Appendix XV)

34. Instructions for collection of PK samples have been updated: Section 6.3.16 (Appendix XV), Section 6.3.16 (Appendix XVII)

35. Statistical considerations for SAB-185 have been updated: Section 10.1.1 (Appendix XV), Section 10.3 (Appendix XV), Section 10.5 (Appendix XV), Section 10.6 (Appendix XV)

36. Risk information for SAB-185 has been updated: Appendix XVI (WHAT ARE THE RISKS OF SAB-185)

37. References for active comparator have been removed: Section 5.1.1 (Appendix XVII), Section 5.1.2 (Appendix XVII), Section 5.2.1 (Appendix XVII), Section 5.2.2 (Appendix XVII), Section 5.3.1 (Appendix XVII)

38. Phase III Schedule of Evaluations has been removed: Section 6.1 (Appendix XVII)

39. Notation has been added that BMS-986414 (C135-LS) and BMS-986413 (C144-LS) consent is only retained for recording purposes: Appendix XVIII